Actively Recruiting
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
Led by Sichuan University · Updated on 2025-07-29
10
Participants Needed
2
Research Sites
49 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Radiopharmaceutical in Relapsed/Refractory Neuroblastoma
CONDITIONS
Official Title
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Relapsed or refractory high-risk neuroblastoma with MIBG avid lesions per Revised International Neuroblastoma Response Criteria (INRC)
- All soft-tissue lesions on CT or MRI must be MIBG-avid
- Age 12 months or older
- Lansky performance status of 50% or higher
- Adequate organ function and hematologic parameters
You will not qualify if you...
- Received antibody-based immunotherapy within 5 half-lives or 30 days, or not recovered from prior biologic therapy adverse reactions
- Treated with I-131 MIBG or Lu-177 targeted radionuclide therapy within 3 months prior
- Autologous transplant less than 12 weeks ago or allogeneic transplant less than 4 months ago; must be free of active GVHD if more than 4 months post-transplant
- Radiotherapy within 2 weeks prior to first dose, except for patients with MIBG uptake after radiotherapy completion; extensive-field radiotherapy within 12 weeks prior
- Presence of renal insufficiency
- Active infections
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
West China Hospital
Chengdu, Sichuang, China
Actively Recruiting
2
West China Hospital
Chengdu, China
Actively Recruiting
Research Team
R
Rong Tian, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here